References

1. Chen YYM, Burne RA. Analysis of Streptococcus salivarius urease expression using continuous chemostat culture. FEMS Microbiol. Letters 1996; 135:223-229.

2. Shannon IL, Prigmore JR. Physiologic chloride levels in human whole saliva. Proc. Soc. Expt. Biol. Med. 1958; 97:825-828.

3. Schenkels L, Veerman ECI, Amerongen AVN. Biochemical composition of human saliva in relation to other mucosal fluids. Crit. Rev. Oral Biol. Med. 1995; 6:161-175.

4. Lindqvist I, Noed CE, Soder PO. Origin of esterases in human whole saliva. Enzyme 1977; 22:166-175.

5. Collins LMC, Dawes C. The surface area of the adult human mouth and thickness of the salivary film covering the teeth and mucosa. J. Dent. Res. 1987; 66:1300-1302.

6. Jenkins GN, Krebsbach PM. Experimental study of the migration of charcoal particles in the human mouth. Arch. Oral Biol. 1985; 30:697-699.

7. Weatherell JA, Robinson C, Rathbone MJ. Site-specific differences in the salivary concentration of substances in the oral cavity—Implications for the aetiology of oral disease and local drug delivery. Adv. Drug Del. Rev. 1994; 13:23-42.

8. Weatherell JA, Robinson C, Ralph JP, Best JS. Migration of fluoride in the mouth. Caries Res. 1984; 18:348-353.

9. Weatherell JA, Strong M, Robinson C, Nakagaki H, Ralph JP. Retention of glucose in oral fluids at different sites in the mouth. Caries Res. 1989; 23:399-405.

10. Sobrero A. Surplusiers composé dé tenants produit avec l'acide nitrique et le sucre, la dextrine, la lactine, la mannite et la glycérine. Comptes, Rendus Hebdomadaires des Séances de l'Academie des Sciences 1847; 24:247-248.

11. Beckett AH, Moffatt AC. The influence of substitution in phenyl acetic acids on their performance in the buccal absorption test. J. Pharm. Pharmacol. 1969; 21:139S.

12. Gandhi RB. Some permselectivity and permeability characteristics of rabbit buccal mucosa. Ph.D. Thesis, University of Wisconsin, Madison 1990.

13. Sadoogh-Abasian F, Evered DF. Absorption of vitamin C from the human buccal cavity. Br. J. Nutr. 1919; 42:15-20.

14. Evered DF, Sadoogh-Abasian F, Patel PD. Absorption of nicotinic acid and nicotimamide across the human buccal mucosa in vivo. Life Sci. 1980; 27:1649-1661.

15. Evered DF, Mallett C. Thiamine absorption across the human buccal mucosa in vivo. Life Sa. 1983; 32:1355-1358.

16. Squier CA, Johnson NW. Permeability of the oral mucosa. Br. Med. Bull. 1975; 31:169-175.

17. Yamahara H, Lee VHL. Drug metabolism in the oral cavity. Adv. Drug Del. Rev. 1993; 12:25-40.

18. Squier CA, Hall BK. The permeability of skin and the oral mucosa to water and horseradish peroxidase as related to the thickness of the permeability barrier. J. Invest. Dermatol. 1985; 84:176-179.

19. Squier CA, Cox PS, Wertz W, Downing DT. The lipid composition of porcine epidermis and oral epithelium. Arch. Oral Biol. 1986; 31:741-747.

20. Curatolo W. The lipoidal permeability barriers of the skin and alimentary tract. Pharm. Res. 1987; 4:271-277.

21. Garza J, Swartzendruber DC, Vincent S, Squier CA, Wertz PW. Membrane structures in the human epithelium (abstract). J. Dent. Res. 1998; 77:1502.

22. Harris D, Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J. Pharmaceut. Sa. 1992; 81:1-10.

23. Squier CA, Rooney L. The permeability of keratinised and non-keratinised oral epithelium to lanthanum in vivo. J. Ultrastruct. Res. 1976; 54:286-295.

24. Cimasoni G. Monographs in oral science, The crevicular fluid. 3 Karger, Basel. 1974.

25. Fine DH, Pechersky JL, McKibben DH. The penetration of human gingival sulcular tissue by carbon particles. Arch. Oral Biol. 1969; 14:1117-1119.

26. McDougall WA. Penetration pathways of a topically applied foreign protein into rat gingiva. J. Periodontal. Res. 1971; 6:89-99.

27. McDougall WA. Ultrastructural localisation of antibody to an antigen applied topically to rabbit gingiva. J. Periodontal. Res. 1972; 7:304-314.

28. Stallard RE, Awwa IA. The effect of alterations in external environment on dento-gingival junction. J. Dent. Res. 1969; 48:671-675.

29. Hansen LB, Christrup LL, Bundgaard H. Ketobemidone prodrugs for buccal delivery. Acta Pharmaceutica Nordica. 1991; 3:77-82.

30. Beckett AH, Triggs ER. Buccal absorption of basic drugs and its application as an in vivo model of passive drug transfer through lipid membranes. J. Pharm. Pharmacol. 1967; 19:31S-41S.

31. Dearden JC, Tomlinson E. Correction for effect of dilution on diffusion through a membrane. J. Pharmaceut. Sci. 1971; 60:1278-1279.

32. Schurmann W, Turner P. A membrane model of the human oral mucosa as derived from buccal absorption performance and physicochemical properties of the beta-blocking drugs atenolol and propranolol. J. Pharm. Pharmacol. 1978; 30:137-147.

33. Tucker IG. A method to study the kinetics of oral mucosal drug absorption from solutions. J Pharm. Pharmacol. 1988; 40:679-83.

34. Kaaber S. Studies on the permeability of human oral mucosa. vi. The mucosal transport of water, sodium and potassium under varying osmotic pressure. Acta Odont. Scand. 1973; 31:307-316.

35. Veillard MM, Longer MA, Martens TW, Robinson JR. Preliminary studies of oral mucosal delivery of peptide drugs. J. Cont. Rel. 1987; 6:123-131.

36. Semple WF. Improved chewing gum. U.S. Patent 98:304 1869.

37. Mulry JT. Nicotine gum dependency: a positive addiction. Drug Intell. Clin. Pharm. 1988; 22:313-314.

38. Rassing MR. Chewing gum as a drug delivery system. Adv. Drug Del Rev. 1994; 13:89121.

39. Christrup LL, Davis SS, Frier M, Melia CD, Rasmussen SN, Washington N, Disposition of a model substance 99m-Tc E-HIDA in the oral cavity, the oesophagus and the stomach during and following administration of lozenges, chewing gum and sublingual tablets, followed by gamma scintigraphy. Int. J. Pharmaceut. 1990; 60:167-174.

40. Andersen T, Gramhansen M, Pedersen M, Rassing MR. Chewing gum as a drug delivery system for nystatin influence of solubilizing agents upon the release of water insoluble drugs. Drug Dev. Indust. Pharm. 1990; 16:1985-1994.

41. Pedersen M, Rassing MR. Miconazole chewing gum as a drug delivery system application of solid dispersion technique and lecithin. Drug Dev. Indust. Pharm. 1990; 16:20152030.

42. Christrup LL, Rasmussen SN, Rassing MR. Chewing gum as a drug delivery system. Proc. 3rd Int Conf. Drug Absorpt. Edinburgh 1988.

43. Aagaard A, Godiksen S, Teglers PT, Schiodt M, Glenert U. Comparison between new saliva stimulants in patients with dry mouth: A placebo-controlled double-blind crossover study. J. Oral Pathol. Med. 1992; 21:376-380.

44. Washington N. Antacids and anti-reflux agents. CRC Press, Boca Raton 1991.

45. Barnett CC, Richardson CT. In vivo and in vitro evaluation of magnesium-aluminium hydroxideantacid tablets and liquid . Dig. Dis. Sci. 1985; 30:1049-1052.

46. Wilson CG, Washington N, Peach J, Murray GR, Kennerley J. The behaviour of a fast-dissolving dosage form (Expidet™) followed by gamma scintigraphy. Int. J. Pharm. 1987; 40:119-123.

47. Nagai T, Machida Y. Buccal delivery systems using hydrogels. Adv. Drug Deliv. Rev 1993; 11:179-191.

48. Schor JM. Sustained release therapeutic compositions. U.S. Patent 4226849 1980.

49. Davis SS, Kennerley JW, Taylor MJ, Hardy JG, Wilson CG. Scintigraphic studies on the in vivo dissolution of a buccal tablet. In Modern Concepts in Nitrate Delivery Systems. Eds Goldberg A.A.J and Parsons D.G. 1983:29-37.

50. Nagai T, Konishi R. Buccal/gingival drug delivery systems. J. Cont. Rel. 1987; 6:353360.

51. Collins AEM, Deasy PB, MacCarthy DJ, Shanley DB. Evaluation of a controlled-release compact containing tetracycline hydrochloride bonded to a tooth for the treatment of periodontal disease. Int. J. Pharmaceut. 1989; 51:103-114.

52. Thorburn DN, Ferguson MM. Topical corticosteroids and lesions of the oral mucosa. Adv. Drug Deliv. Rev. 1994; 13:135-149.

53. Nagai T, Machida Y. Advances in drug delivery—mucoadhesive dosage forms. Pharm. Int. 1985; 6:196-200.

54. Naito H, Matsuda Y, Shiomi K, Yorozu T, Maeda T, Lee H, et al. Effects of sublingual nitrate in patients receiving sustained therapy of isosorbide dinitrate for coronary artery disease. Am. J. Cardiol. 1989; 64:565-568.

55. Yukimatsu K, Nozaki Y, Kakumoto M, Ohta M. Development of a trans-mucosal controlled-release device for systemic delivery of antianginal drugs pharmacokinetics and pharmacodynamics. Drug Develop. Indust. Pharm. 1994; 20:503-534.

56. Wagner F, Siefert F, Trenk D, Jahnchen E. Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate. Europ. J. Clin. Pharmacol. 1990; 38 (Suppl 1):S53-S59.

57. Nyberg G. Onset time of action and duration up to 3 hours of nitroglycerin in buccal, sublingual and transdermal form. Europ. Heart J. 1986; 7:673-678.

58. Ryden L, Schaffrath R. Buccal versus sublingual nitroglycerin administration in the treatment of angina pectoris: a multi centre study. Europ. Heart J. 1987; 8:994-1001.

59. Anderson E, Haymaker W, Henderson E. Successful sublingual therapy in Addison's disease. J. Am. Med. Assoc. 1940; 115:216-217.

60. Miescher K, Gasche P. Zur lingualen Applikation von männlichem sexualhormon; Beitrag zur Therapie mit "Perandren-Linguetten". Schweiz. Med. Wochenschr. 1942; 72:279-281.

61. Escamilla RF, Bennett LL. Pituitary infantilism treated with purified growth hormone, thyroid and sublingual methyltestosterone. Case report. J. Clin. Endocrinol. 1951; 11:221.-228.

62. Thorburn DN, Ferguson MM. Topical corticosteroids and lesions of the oral mucosa. Adv. Drug Deliv. Rev. 1994; 13:135-149.

63. Bardgett D, Howard C, Murray GR, Calvey TN, Williams NE. Plasma concentration and bioavailability of buccal preparation of morphine sulphate. Br. J. Clin. Pharmacol. 1984; 17:198P- 199P.

64. Bell MDD, Murray GR, Mishra P, Calvey TN, Weldon BD, Williams NE. Buccal morphine—a new route for analgesia? Lancet 1985; i:71-73.

65. Fisher AP, Vine P, Whitlock J, Hanna M. Buccal morphine premedication. Anaesthesia 1986; 41:1104-1111.

66. Fisher AP, Fung C, Hanna M. Serum morphine concentrations after buccal and intramuscular morphine administration. Br. J. Clin. Pharmacol. 1987; 24:685-687.

67. Samaranayake LP. Oral mycoses in HIV infection. Oral Surg. Oral Med. Oral Pathol. 1990; 73:171-180.

68. Samaranayake LP, Ferguson MM. Delivery of antifungal agents to the oral cavity. Adv. Drug Deliv. Rev. 1994; 13:161-179.

69. Nair MK, Chien YW. Development of anticandidal delivery systems: (II) Mucoadhesive devices for prolonged drug delivery in the oral cavity. Drug Dev. Indust. Pharm. 1996; 22:243-253.

70. Fujioka N, Akazawa R, Sakamoto K, Ohashi K, Kurimoto M. Potential application of human interferon-alpha in microbial infections of the oral cavity. J. Interferon Cytokine Res. 1995; 15:1047-1051.

71. Asthana OP, Woodcock BG, Wenchel M, Frömming KH, Schwabe L, Rietbrock N. Verapamil disposition and effects on PQ intervals after buccal, oral and intravenous administration. Drug Res. 1984; 34:498-502.

72. Robinson BF, Dobbs RJ, Kelsey CR. Effects of nifedipine on resistance of vessels, arteries and veins in man. Br. J. Clin. Pharmacol. 1980; 10:433-438.

73. Miller GW. Induction of labour by buccal administration of oxytocin. J. Am. Osteopath. Assoc. 1974; 72:1110-1113.

74. Merkle HP, Wolany G. Buccal delivery for peptide drugs. J. Cont. Rel. 1992; 21:155-164.

Was this article helpful?

0 0
The Natural Acne Remedy

The Natural Acne Remedy

Download this Guide and Discover 50 Ways To Treat Acne Using Only Natural Remedies. About Time You Got Rid of Your Acne? Inside this guide, you'll discover: 50 ways to treat acne using natural remedies. The benefits of treating acne using natural remedies. Natural acne remedies to treat acne scarring. The side effects of popular acne medicines and treatments plus much, much more.

Get My Free Ebook


Post a comment